Dr. Reddy's Laboratories Ltd. closed 16.71% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr. Reddy's Laboratories Ltd. closed 17.18% below its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...

HYDERABAD: Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian arm, Sanofi Healthcare India Pvt Ltd (SHIPL), to bring a ...

Dr Reddys Laboratories shares experienced a notable surge in trading volume during today's session, accompanied by a 1.18% increase in price intraday, reaching Rs 1190.00. The increased activity ...

Dr Reddy's Laboratories on Monday said it has expanded its partnership with Sanofi Healthcare to introduce a novel drug for the prevention of lower respiratory tract disease in newborns.

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India. Containing monoclonal antibody ...

Dr Reddys Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses ...

Dr Reddy’s Laboratories expands its strategic partnership with Sanofi Healthcare India to introduce a novel drug, Beyfortus (nirsevimab), in India. Beyfortus contains the monoclonal antibody, ...

Under the arrangement, Dr Reddy's will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.

HYDERABAD: Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant ...